durvalumab and tremelimumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Transitional Cell Carcinoma of the Urothelial Tract
Conditions
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Metastatic Bladder Cancer
Trial Timeline
Jan 31, 2018 → Feb 10, 2021
NCT ID
NCT03430895About durvalumab and tremelimumab
durvalumab and tremelimumab is a phase 2 stage product being developed by AstraZeneca for Non-Transitional Cell Carcinoma of the Urothelial Tract. The current trial status is completed. This product is registered under clinical trial identifier NCT03430895. Target conditions include Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03430895 | Phase 2 | Completed |